Sexually Transmitted Diseases

Resources

Basic InformationMore InformationLatest News

HIV Virus May Hide in BrainHIV in Blood Different Than in Semen, Scientists SayAdding Third Drug May Improve Hepatitis C TreatmentIAC: Highly Active Antiretroviral Therapy Halves New HIV CasesNew Guidelines Urge Earlier Therapy for HIV PatientsNew Methods May Help Predict Survival of African HIV PatientsBenefits Seen With Early Antiretroviral Therapy in HIVStudy Suggests Link Between HPV, Skin CancerDrugs Like Viagra Linked to Higher Rates of STDsScientists Make Immune Cells in Mice That Fight Off HIVRapid Test to Detect Hepatitis C ApprovedNewly Approved HIV Test Can Spot Infection EarlierAntiretrovirals During Breast-Feeding Shield Babies From HIV, Study ShowsOld Drugs May Have New Use Against Hepatitis CMost People With HIV Begin Care Too LateAnti-HIV Drugs May Help Prevent Spread of VirusScientists Unravel Secret of HIV ResistanceIn Early Test, New Hepatitis C Drug Shows PromiseMorphine May Protect Brains of People With HIVStudy Questions Effectiveness of Single Chlamydia TestMore Clues Emerge on How HIV Infects WomenNew Drug Shows Promise for Curing Hepatitis CScientists Find Clues to How the Body Fights Off HIVWomen Would Welcome At-Home Test for STDsHerpes Infects One in Six in U.S.HIV Hides Out in Bone Marrow CellsResistance Likely to Develop With New Hepatitis C DrugsGene Therapy Shows Promise Against HIVTreating Herpes May Slow HIV in Co-Infected PatientsScientists Discover How HIV Is Transmitted Between MenFDA Revises Label for the HIV Drug DidanosinePremature Aging of the Brain Seen in HIV PatientsDrug Combo Blocks HIV Infection in MiceNew Treatment Eyed for Hepatitis CEvolving Strains of HIV May Cause Wave of Drug ResistanceHIV Infection May Increase Fracture Risk in WomenMolecule Could Help Block Sexual Transmission of HIVScientists Spot Source of Hurdle to AIDS VaccineHPV Vaccine Can Maintain Effectiveness Beyond Six YearsNew Hepatitis C Treatment Shows PromiseTenofovir DF-Emtricitabine Is Effective Initial HIV TherapyOne in Four Teen Girls Have STDsGenetic Variant Slows AIDS ProgressionGenital Herpes May Never Go DormantTeen Girls at Higher Risk for STDs: ReportSperm May Play Role in Transmission of HIVHPV Vaccine No More Painful Than Other ShotsCDC Panel Says No to Routine Use of Gardasil for BoysCost, Efficacy of HPV Vaccine in Older Women ExploredHIV Vaccine Regimen Shows Modest Benefits

Questions and AnswersLinksBook Reviews

Related Topics

Homosexuality & Bisexuality

HIV Vaccine Regimen Shows Modest Benefits

by -- Andrea Mongler
Updated: Oct 20th 2009

new article illustration

TUESDAY, Oct. 20 (HealthDay News) -- A vaccine combination may decrease the risk of HIV infection in a community-based population that has a largely heterosexual risk, according to a study published online Oct. 20 in the New England Journal of Medicine to coincide with the AIDS Vaccine Conference, held from Oct. 19 to 22 in Paris.

Supachai Rerks-Ngarm, M.D., of the Ministry of Public Health in Bangkok, Thailand, and colleagues performed a randomized, community-based, double-blind, placebo-based trial, in which they injected 16,402 healthy men and women with four priming injections of the recombinant canarypox vector vaccine ALVAC-HIV and two booster injections of the recombinant glycoprotein 120 subunit vaccine AIDSVAX B/E. The subjects were between 18 and 30 years of age and primarily at heterosexual risk for HIV infection.

In an intention-to-treat analysis involving all vaccine recipients, the researchers found that the vaccine efficacy was 26.4 percent. In a per-protocol analysis that involved 12,452 vaccine recipients, the vaccine efficacy was 26.2 percent, and there was a vaccine efficacy of 31.2 percent in a modified intention-to-treat analysis involving all 16,402 recipients, except seven who were found to have had HIV-1 infection at baseline. In subjects later diagnosed with HIV-1, vaccination didn't affect degree of viremia or CD4+ T-cell count.

"Although our study provided preliminary evidence that an HIV vaccine regimen has the potential to prevent infection, it did not have the power to address two intriguing considerations: vaccine efficacy may have decreased over the first year after vaccination, and vaccine efficacy may have been greater in persons at lower risk for infection," the authors conclude.

Sanofi Pasteur provided the ALVAC-HIV vaccine for the study, and three of the researchers reported being employees of the company.

Abstract
Full Text
Editorial

This article: Copyright © 2009 ScoutNews, LLC. All rights reserved.